CVS Health (CVS) — The Transparent Read
73/100Bullish$103.58 · uptrend
The weight of evidence leans bullish. Long-term and medium-term trends are aligned, momentum is positive, and the macro regime historically favors upside with a median +3.0% over 90 days. The single biggest caveat is the proximity to resistance at $106.15 — that's the line in the sand. I'd treat a decisive close above it as confirmation that the next leg higher is underway; until then, expect some chop as the stock digests its run. Net lean: constructive, with patience required at resistance.
CVS key levels
Show Your Work — every point in CVS's score
The score starts at 50, then each signal below adds or subtracts points. No black box.
| Signal | Type | Points |
|---|---|---|
| Above 200-day MA Price is above its 200-day average — long-term trend is up. | technical | +8 |
| Above 50-day MA Trading above the 50-day average — medium-term momentum is positive. | technical | +5 |
| Golden cross 50-day average is above the 200-day (golden cross). | technical | +4 |
| RSI neutral RSI is 68 — neither overbought nor oversold. | technical | +1.83 |
| MACD positive MACD is above its signal line — momentum is building. | technical | +5 |
| Near resistance Pressing against resistance around $106.15. | technical | -4 |
| Macro regime base rate In 38 past periods like today (Rising inflation + Steady Fed), this stock was higher 90d later 63% of the time (median +3.0%). Historically favorable. | macro | +2.63 |
Macro regime base rate
Today's regime: Rising inflation + Steady Fed
In 38 past periods that looked like today, CVS was higher 90 days later 63% of the time (median move 3.0%). Confidence: high.
The read
CVS Rides a Healthy Uptrend Into Resistance at $106
Bull case. This is a textbook uptrend. CVS trades at $103.58, comfortably above both its 50-day MA ($91.73) and 200-day MA ($80.25), with a golden cross confirming the longer-term turn higher. Momentum is constructive: the MACD histogram is positive (+0.12) with the line above its signal, and RSI at 68 is firm without being stretched. The composite score of 72.5/100 lands squarely in bullish territory. Macro tailwinds back this up — in 38 analogous Rising-Inflation/Steady-Fed regimes, CVS was higher 90 days later 63% of the time with a median gain of +3.0% (high confidence). Clear a break above $106.15 and the path of least resistance is up.
Bear case. The most immediate hurdle is right overhead: CVS is pressing against resistance at $106.15, a level that earned a -4.0 in the signal breakdown. RSI at 68 is knocking on the door of overbought, so the easy momentum may be behind us in the near term. If buyers can't punch through resistance, a pullback toward the 50-day MA ($91.73) or even support at $89.42 is on the table. And the base rate cuts both ways — 37% of analogous periods finished lower 90 days out.
What would change my mind. A decisive close back below the 50-day MA at $91.73 would break the medium-term momentum structure and flip this read to cautious. A failure at $106.15 followed by a slide toward support at $89.42 would confirm the bears have the upper hand.
CVS — frequently asked
Is CVS a buy according to Tallyread?
Tallyread does not give buy or sell recommendations. It shows a transparent 73/100 read for CVS Health (CVS), conditioned on today's macro regime, with every scoring input itemized so you can judge for yourself. This is not financial advice.
How is CVS's Tallyread score calculated?
The 73/100 score starts at 50, then adds and subtracts named technical and macro signals — each shown with its point value and a one-line reason in the "Show Your Work" table on this page. Nothing is hidden in a black box.
How does today's Fed-and-inflation regime affect CVS?
In 38 past periods whose macro regime matched today's (Rising inflation + Steady Fed), CVS was higher 90 days later 63% of the time, with a median move of 3.0%. Confidence: high.
Want a fresh read on CVS with the live chart and macro tape?
Run a live CVS read →Last analyzed 2026-06-30 · Data source: tiingo. See the public scorecard and methodology.
This is a historical and technical read for informational and educational purposes only — not financial advice, and not a recommendation to buy or sell CVS. Markets are uncertain; do your own research.